Core Viewpoint - Cellyan Biotechnology Co., Ltd has received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement for its class A ordinary shares, which have been below US$1.00 for 30 consecutive business days [1][2]. Compliance Status - The notification does not affect the current trading status of the company's shares, which will continue to trade on Nasdaq under the ticker "HKPD" [2]. - The company has a compliance period of 180 calendar days, until July 13, 2026, to regain compliance with the minimum bid price rule [3]. - If the share price reaches US$1.00 or above for at least ten consecutive business days during this period, Nasdaq will confirm compliance [3]. Potential Actions - If compliance is not regained by July 13, 2026, the company may be eligible for an additional 180-day grace period, provided it meets other listing requirements [4]. - The company may consider options such as a reverse share split to regain compliance, which must be completed no later than 10 business days prior to the end of the second compliance period [4]. Company Overview - Cellyan Biotechnology Co., Ltd specializes in OTC pharmaceutical cross-border e-commerce supply chain services and operates through its subsidiaries [5]. - The company provides a comprehensive range of services including product procurement, logistics, and end-to-end delivery for Mainland Chinese customers seeking OTC pharmaceutical products from outside China [6][7].